실적분석 2026년 8월 10일

Alcon ($ALC) Q2 2026 Earnings Analysis — Core EPS Beats Expectations, Full-Year Outlook Raised

Earnings Scorecard

Revenue: $2.782 billion (+8% year-over-year, consensus $2.77 billion) ✅ Beat

EPS: Core (adjusted) diluted EPS $0.84 (consensus $0.75) ✅ Beat

Guidance: Raised — full-year core operating margin (+90 to +190 bp) and core diluted EPS growth (+12% to +15%, constant currency) raised; revenue growth (+5% to +7%, constant currency) maintained

Stock reaction: +4.58% after-hours ($77) — as of 08-11 05:59 KST

The Positives

Core earnings beat: Core diluted EPS of $0.84 exceeded the $0.75 consensus

New-product momentum: Unity, PanOptix Pro, and Tryptyr led growth

Full-year outlook raised: Core operating margin and core EPS growth guidance upgraded

Eye-care specialist Alcon saw both its Surgical and Vision Care segments grow 8% year-over-year, confirming solid top-line momentum. Core operating margin also expanded to 20.6% from 19.1% a year earlier, signaling improvement in underlying profitability.

The Negatives

One-time charge: $402 million pre-tax non-cash charge tied to the PowerVision discontinuation

Accounting earnings gap: IFRS diluted EPS of $0.00 (vs. $0.35 a year ago)

Market and tariff pressure: Cataract market softness and full-year net tariff impact of $40 million to $90 million

IFRS operating profit fell sharply to $11 million from $247 million a year earlier, but the decline was largely driven by non-cash charges related to PowerVision. Implant growth slowed amid competitive pressure and weakness in surgical glaucoma, and tariffs remain a margin variable for the second half.

What Management Said

The CEO noted that recent launches are fueling growth and that market position is expanding, including in contact lenses. The company held its full-year revenue growth outlook unchanged while raising only core profit guidance, reflecting confidence in underlying margin improvement.

Market Reaction and What to Watch

The core EPS beat and raised full-year profit outlook appear to have overshadowed the accounting earnings gap from one-time charges, driving a positive reception.

Watch whether Unity equipment and PanOptix Pro IOL revenue acceleration sustains growth in the Surgical segment.

Monitor whether Tryptyr and Systane dry-eye products maintain momentum in the Vision Care segment.

Track the net tariff impact range and the effect of any Q3 rebate reflection on core margins.